These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 20814306)

  • 21. Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new?
    Soulsby N; Bell S; Greville H; Doecke C
    Intern Med J; 2009 Aug; 39(8):527-31. PubMed ID: 19220547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aminoglycoside induced ototoxicity in patients with cystic fibrosis.
    Mulherin D; Fahy J; Grant W; Keogan M; Kavanagh B; FitzGerald M
    Ir J Med Sci; 1991 Jun; 160(6):173-5. PubMed ID: 1752740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin.
    Powell SH; Thompson WL; Luthe MA; Stern RC; Grossniklaus DA; Bloxham DD; Groden DL; Jacobs MR; DiScenna AO; Cash HA; Klinger JD
    J Infect Dis; 1983 May; 147(5):918-32. PubMed ID: 6860416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.
    Harruff EE; Kil J; Ortiz MGT; Dorgan D; Jain R; Poth EA; Fifer RC; Kim YJM; Shoup AG; Flume PA
    J Cyst Fibros; 2021 Mar; 20(2):288-294. PubMed ID: 33341407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM; Waugh J; Noble S
    Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progressive Hearing Loss among Patients with Cystic Fibrosis and Parenteral Aminoglycoside Treatment.
    Zettner EM; Gleser MA
    Otolaryngol Head Neck Surg; 2018 Nov; 159(5):887-894. PubMed ID: 29914288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis.
    Akbar A; Rees JH; Nyamugunduru G; English MW; Spencer DA; Weller PH
    Acta Paediatr; 1999 Jul; 88(7):783-5. PubMed ID: 10447142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case-control study of acute renal failure in patients with cystic fibrosis in the UK.
    Smyth A; Lewis S; Bertenshaw C; Choonara I; McGaw J; Watson A
    Thorax; 2008 Jun; 63(6):532-5. PubMed ID: 18245146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended-interval aminoglycoside administration for children: a meta-analysis.
    Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
    Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients.
    LeCleir LK; Pettit RS
    Pediatr Pulmonol; 2017 Aug; 52(8):1000-1005. PubMed ID: 28440913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
    Ratjen F; Brockhaus F; Angyalosi G
    J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: A systematic review.
    Farzal Z; Kou YF; St John R; Shah GB; Mitchell RB
    Laryngoscope; 2016 Jan; 126(1):228-35. PubMed ID: 26152803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR; Bhatt J
    Cochrane Database Syst Rev; 2012 Feb; (2):CD002009. PubMed ID: 22336782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.
    Al-Aloul M; Miller H; Alapati S; Stockton PA; Ledson MJ; Walshaw MJ
    Pediatr Pulmonol; 2005 Jan; 39(1):15-20. PubMed ID: 15521084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antibiotic-induced diseases. Aminoglycoside-induced renal lesions].
    Gioannini P
    Minerva Med; 1978 Dec; 69(61):4215-25. PubMed ID: 366465
    [No Abstract]   [Full Text] [Related]  

  • 37. [Prediction of aminoglycoside nephrotoxicity (author's transl)].
    Whelton A
    Nouv Presse Med; 1978 Nov; 7(42):3838-43. PubMed ID: 714689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypersensitivity to inhaled TOBI following reaction to gentamicin.
    Spigarelli MG; Hurwitz ME; Nasr SZ
    Pediatr Pulmonol; 2002 Apr; 33(4):311-4. PubMed ID: 11921461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum.
    Mendelman PM; Smith AL; Levy J; Weber A; Ramsey B; Davis RL
    Am Rev Respir Dis; 1985 Oct; 132(4):761-5. PubMed ID: 3931522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR; Tan KH
    Cochrane Database Syst Rev; 2006 Jul; (3):CD002009. PubMed ID: 16855982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.